

Infection and non-union of the upper and lower part of the shinbone: treatment with the Ilizarov method

Submission date 18/01/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 25/01/2022	Overall study status Completed	<input checked="" type="checkbox"/> Protocol
Last Edited 30/12/2022	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

An infected non-union (not fully healed) fracture in the lower or distal part of the tibia (shinbone) is a rare condition that can be disastrous. The neighbour joint could be affected and the bone axis could alter. Patients with this condition have to cope with pain, limited physical activity, inability to work and low quality of life. The goal of any surgical treatment is the eradication of the infection, dealing with any bone loss and the healing of the fracture. All the above should be planned and done at the same time. In case of treatment failure even amputation of the limb is an option. In this study, the Ilizarov method, a type of external fixation with circular frames, will be tested.

Who can participate?

Patients with an infected non-union fracture in the upper or distal part of the tibia

What does the study involve?

All participants undergo treatment of non-union and infection after surgical cleansing, antibiotic treatment and placement of the Ilizarov apparatus. The patient's clinical and functional outcomes and feelings of pain are measured before the surgery and afterwards throughout the follow-up period at regular intervals. The duration of follow-up is 36 months (3 years).

What are the possible benefits and risks of participating?

The goal of the treatment is fracture healing and infection eradication. This will improve the quality of life of the participant (return to work, return to daily or sports activity). Other options for these patients include arthrodesis (fusions of the bones resulting in a knee or ankle without any range of motion) or even amputation. As the Ilizarov method is approved and known for 80 years possible risks will not arise from the treatment itself but from the patients' other illnesses and the common risks of any other surgery.

Where is the study run from?

June 2020 to June 2024

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
1. Prof. Andreas Panagopoulos, andpan21@gmail.com
2. Dr Konstantinos Sidiropoulos, kcdroq@yahoo.gr

Contact information

Type(s)

Principal investigator

Contact name

Dr Konstantinos Sidiropoulos

ORCID ID

<https://orcid.org/0000-0002-9627-465X>

Contact details

General Hospital of Serres
Orthopaedic Department
2nd Km Serron-Dramas, 62100
Thessaloniki
Greece
54655
+30 (0)6974709428
up1089676@upatras.gr

Type(s)

Principal investigator

Contact name

Prof Andreas Panagopoulos

ORCID ID

<https://orcid.org/0000-0002-8215-9327>

Contact details

Orthopaedic Clinic
Patras University Hospital
Patras
Greece
26504
+30 (0)6944363624
anpanagop@upatras.gr

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

University of Patras, School of Medicine 20-11-2020, 5141/38886

Study information

Scientific Title

Treatment of septic metaphyseal non-union of tibia using the Ilizarov method

Acronym

SePseT Ilizarov

Study objectives

The Ilizarov apparatus completely and successfully treats septic pseudoarthrosis proximal and distal tibia metaphysis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Approved 30/09/2020, the General Hospital of Serres Ethics and Scientific Committee (3rd Km Serron-Dramas, Serres, Greece, 62100; +30 (0)2321094549; gnserres@hospserres.gr), ref: 09/21-09-2020
2. Approved 04/09/2020, the General Hospital of Drama Ethics and Scientific Committee (57 Ippokratous Street, 66100, Drama, Greece; +30 (0)25213 50300; iatriki.upiresia@dramahospital.gr), ref: 336/2020

Study design

Multicenter interventional non-randomized trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Patients with closed epiphyses with metaphyseal non-union in tibia which are infected with pathogens

Interventions

The intervention studied is the treatment of pseudoarthrosis and infection after surgical cleansing, antibiotic treatment and placement of the Ilizarov apparatus. The patient's clinical and functional outcomes are taken into account as well as subjective feelings of pain and the change of all these preoperatively and postoperatively throughout the follow-up period at predetermined regular intervals. The duration of follow-up is 36 months (3 years).

Intervention Type

Procedure/Surgery

Primary outcome(s)

1. Treatment success assessed using:
 - 1.1. Healed fracture/non-union assessed using x-rays at pre-op, every month after Ilizarov removal and every 6 months up to the end of the follow-up period (min. 3 years)
 - 1.2. Eradication of infection assessed using biomarkers (CRP, ESR, white blood count) at pre-op, every month after Ilizarov removal and every 6 months up to the end of the follow-up period (min. 3 years)
2. Treatment failure will be assessed by clinical examination and radiological evaluation monthly postoperatively until Ilizarov removal (end of the treatment period) and once per semester until the end of the follow-up period (3 years)
3. Side effects will be recorded when they appear either with modification of antibiotic therapy or calibration and cleaning of the Ilizarov device

Key secondary outcome(s)

1. Functionality of the limb calculated with the AOFAS score/KOS-ADSL (Greek version) at pre-op, 1 month after Ilizarov removal and every 6 months up to the end of the follow-up period (min. 3 years)
2. Quality of life assessed with the Short Form-12 (Mental Health) at pre-op, 3 months, 6 months, 1 month after Ilizarov removal and every 6 months up to the end of the follow-up period (min. 3 years)
3. General lower limb condition measured using the ALOS Lower Limb Core Scale at pre-op, 1 month after Ilizarov removal and every 6 months up to the end of the follow-up period (min. 3 years)
4. Pain measured using the Visual Analog Pain scale once per month until the removal of Ilizarov device and once each semester until the end of the follow-up period
5. Quality of life measured using QALY analysis and the Time Trade-off index at pre-op, 1 month after Ilizarov removal and every 6 months up to the end of the follow-up period (min. 3 years), and EQ-5D-3L at pre-op, 3 months, 6 months, 1 month after Ilizarov removal and every 6 months up to the end of the follow-up period (min. 3 years)
6. Limb discrepancy, where it exists, measured clinically, radiologically and functionally with the use of wooden wedges (use of the ASAMI score for bone health and function of the limb) at pre-op, 3 months, 6 months, 1 month after Ilizarov removal and every 6 months up to the end of the follow-up period (min. 3 years)

Completion date

30/06/2024

Eligibility

Key inclusion criteria

The participants in the study:

1. Must have completed their skeletal development by closing the epiphyses in the proximal and distal metaphysis of the tibia
2. Have septic pseudoarthrosis at the examined points
3. Freely consent to this study

Patients with concomitant health problems or immunosuppressed ones are not excluded from the study as long as they meet the above criteria

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Underage patient or open epiphyses
2. Absence of infection
3. Infected non-union in another part of the tibia or anywhere else
4. No signed consent form

Date of first enrolment

01/12/2020

Date of final enrolment

31/12/2023

Locations**Countries of recruitment**

Greece

Study participating centre

General Hospital of Serres

2nd Km Serron-Dramas

Serres

Greece

62100

Study participating centre

General Hospital of Drama

57 Ippokratous Street

Drama

Greece

66100

Sponsor information

Organisation

General University Hospital of Patras

ROR

<https://ror.org/03c3d1v10>

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the subsequent results publication

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		29/12/2022	30/12/2022	Yes	No